Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.

JCI Insight · 2022 · PMC9310528 · PMID 35801592

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In the PDX study, we observed an increasing trend of human GDF-15 levels 24 hours after administration of milademetan on day 4 but not on day 21 ( Supplemental Figure 4 , C and D).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.